ANNX · Annexon, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $184.70M | $119.45M | $113.76M | $112.50M | $100.07M | $49.27M |
| SG&A | $31.71M | $34.63M | $29.97M | $33.10M | $30.65M | $14.20M |
| Total Operating Expenses | $216.41M | $154.07M | $143.72M | $145.60M | $130.71M | $63.47M |
| D&A | $2.17M | $2.15M | $2.15M | $2.11M | $2.14M | $667.0K |
| Operating Income | ($216.41M) | ($154.07M) | ($143.72M) | ($145.60M) | ($130.71M) | ($63.47M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | - | $4.0K |
| Net Income | ($206.69M) | ($138.20M) | ($134.24M) | ($141.95M) | ($130.32M) | ($63.41M) |
| EPS - Basic | ($1.34) | ($1.01) | ($1.77) | ($3.40) | - | - |
| EPS - Diluted | ($1.34) | ($1.01) | ($1.77) | ($2.60) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $162.05M | $49.50M | $225.11M | $140.02M | $74.84M | $268.56M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $14.93M | $10.43M | $5.49M | $7.42M | $11.15M | $3.73M |
| Current Assets | $242.19M | $316.46M | $263.86M | $248.10M | $247.69M | $354.01M |
| Total Assets | $277.57M | $350.07M | $297.67M | $285.10M | $287.04M | $355.95M |
| Current Liabilities | $42.63M | $30.51M | $17.93M | $22.36M | $21.74M | $10.62M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $65.92M | $56.97M | $47.12M | $53.90M | $55.13M | $11.67M |
| Stockholders' Equity | $211.65M | $293.11M | $250.56M | $231.19M | $231.91M | $344.28M |
| Retained Earnings | ($917.39M) | ($710.70M) | ($572.50M) | ($438.26M) | ($296.31M) | ($165.99M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($186.36M) | ($118.01M) | ($121.14M) | ($116.31M) | ($106.11M) | ($53.09M) |
| Investing Cash Flow | $190.05M | ($218.80M) | $70.70M | $58.44M | ($88.24M) | ($83.16M) |
| Financing Cash Flow | $108.86M | $161.21M | $135.52M | $122.91M | $1.79M | $360.88M |
| CapEx | $137.0K | $15.0K | $193.0K | $6.53M | $1.65M | $464.0K |
| Free Cash Flow | ($186.49M) | ($118.02M) | ($121.33M) | ($122.83M) | ($107.76M) | ($53.55M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.90 | 0.85 | 0.90 | 0.87 | 0.83 | 0.84 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -74.5% | -39.5% | -45.1% | -49.8% | -45.4% | -17.8% |
| Return on equity | -97.7% | -47.2% | -53.6% | -61.4% | -56.2% | -18.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 5.68 | 10.37 | 14.72 | 11.10 | 11.39 | 33.33 |
| Quick ratio | 5.68 | 10.37 | 14.72 | 11.10 | 11.39 | 33.33 |
| Cash ratio | 3.80 | 1.62 | 12.56 | 6.26 | 3.44 | 25.28 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.31 | 1.19 | 1.19 | 1.23 | 1.24 | 1.03 |
| Liabilities / Assets | 0.24 | 0.16 | 0.16 | 0.19 | 0.19 | 0.03 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 3.7x | 2.4x | 1.4x | 0.9x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -40.5% | -7.2% | 1.3% | -11.4% | -105.9% | - |
| Net income growth (YoY) | -49.6% | -3.0% | 5.4% | -8.9% | -105.5% | - |
| EPS growth (YoY) | -32.7% | 42.9% | 31.9% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -58.0% | 2.7% | 1.2% | -14.0% | -101.2% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -27.8% | 17.0% | 8.4% | -0.3% | -32.6% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Annexon against the 5 most active filers in the same SIC group.